Andrew Good, D.Phil., joined Expansion Therapeutics in July of 2021 as the Vice President of computational chemistry. Andrew has over 30 years of experience applying and developing computational chemistry techniques within drug discovery programs. He has served in multiple senior scientific roles, including Distinguished Scientific fellow at Genzyme and most recently Senior Director of CADD / cheminformatics at C4 Therapeutics. Andrew is a co-inventor on 14 projects that have led to IND candidate nomination including the HCV drugs Daclatasvir and Asunaprevir, resulting in a 2017 ACS heroes of chemistry award. He has pioneered several widely applied CADD techniques, including pharmacophore constraint usage, 3D pharmacophore fingerprints and Gaussian function approximations for molecular similarity calculations. Andrew has authored over 100 research articles and is a co-inventor on more than 50 patents. Dr. Good received his D.Phil. from Oxford University where his studies focused on the development of novel computational methods for the rapid determination of 3D molecular similarity. He completed his postdoctoral studies at the University of California San Francisco and holds a BSc in chemistry from Nottingham University.